专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

21. 发明授权

US07232881B2 Peptide containing Ser-Ser-Ser-Arg 有权
标题翻译：含Ser-Ser-Ser-Arg的肽
公开(公告)号：US07232881B2
公开(公告)日：2007-06-19
申请号：US10497628
申请日：2002-12-03
申请人： Teruo Nishida , Makoto Inui , Masatsugu Nakamura
发明人： Teruo Nishida , Makoto Inui , Masatsugu Nakamura
IPC分类号： C07K5/10 , A61K38/00 , A61K38/02 , A61K38/10 , A61K38/08 , A61K38/07 , C07K2/00 , C07K7/04 , C07K7/08
CPC分类号： A61K38/30 , A61K9/0048 , C07K5/1013 , C07K5/1016 , C07K14/65
摘要： A peptide, wherein the peptide is selected from the group consisting of Ser-Ser-Ser-Arg (SEQ ID NO: 1), Gly-Ser-Ser-Ser-Arg-Arg-Ala-Pro (SEQ ID NO: 4), Ser-Ser-Ser-Arg-Arg (SEQ ID NO: 5), Gly-Ser-Ser-Ser-Arg (SEQ ID NO: 6), Gly-Ser-Ser-Ser-Arg-Arg (SEQ ID NO: 7), Ala-Ser-Ser-Ser-Arg-Arg-Ala-Pro (SEQ ID NO: 8), Gly-Ser-Ser-Ser-Arg-Ala-Ala-Pro (SEQ ID NO: 9) and Gly-Ser-Ser-Ser-Arg-Ala-Ala-Ala-Pro (SEQ ID NO: 10), or a pharmaceutically acceptable salt thereof.
摘要翻译：肽，其中肽选自Ser-Ser-Ser-Arg（SEQ ID NO：1），Gly-Ser-Ser-Ser-Arg-Arg-Ala-Pro（SEQ ID NO：4），Ser-Ser-Ser-Arg-Arg（SEQ ID NO：5），Gly-Ser-Ser-Ser-Arg（SEQ ID NO：6），Gly-Ser-Ser-Ser-Arg-Arg ：Ala-Ser-Ser-Ser-Arg-Arg-Ala-Pro（SEQ ID NO：8），Gly-Ser-Ser-Ser-Arg-Ala-Ala-Pro（SEQ ID NO：9）和 Gly-Ser-Ser-Ser-Arg-Ala-Ala-Ala-Pro（SEQ ID NO：10）或其药学上可接受的盐。

22. 发明申请

US20050009752A1 Novel peptides and medicinal uses thereof 有权
标题翻译：新型肽及其药用用途
公开(公告)号：US20050009752A1
公开(公告)日：2005-01-13
申请号：US10497628
申请日：2002-12-03
申请人： Teruo Nishida , Makoto Inui , Masatsugu Nakamura
发明人： Teruo Nishida , Makoto Inui , Masatsugu Nakamura
IPC分类号： A61K9/00 , A61K38/00 , A61K38/30 , A61P17/02 , A61P27/02 , C07K5/103 , C07K5/107 , C07K14/65 , A61K38/08 , C07K7/06
CPC分类号： A61K38/30 , A61K9/0048 , C07K5/1013 , C07K5/1016 , C07K14/65
摘要： It is an object of the invention to examine the minimum unit of the exhibition of the activity of insulin-like growth factor-I and find a pharmaceutical use thereof in the fields of ophthalmology and dermatology. A joint administration of a peptide containing the amino acid sequence represented by Ser-Ser-Ser-Arg as the minimum unit of the exhibition of the activity of insulin-like growth factor-I and a peptide containing the amino acid sequence represented by Phe-Gly-Leu-Met-NH2 is effective for curing corneal disorders and can significantly promote the healing of skin wounds.
摘要翻译：本发明的目的是检查胰岛素样生长因子-I的活性展示的最小单位，并在眼科和皮肤病领域找到其药物用途。包含由Ser-Ser-Ser-Arg表示的氨基酸序列的肽的共同给药作为胰岛素样生长因子-I的活性的展开的最小单位和含有Phe- Gly-Leu-Met-NH2对于治疗角膜疾病有效，可以显着促进皮肤伤口的愈合。

23. 发明授权

US06311027B1 Image-forming apparatus which forms images by using a developer 有权
标题翻译：通过使用显影剂形成图像的图像形成装置
公开(公告)号：US06311027B1
公开(公告)日：2001-10-30
申请号：US09477628
申请日：2000-01-04
申请人： Hirofumi Sakita , Syouichi Fujita , Hideji Saiko , Mitsuru Tokuyama , Masatsugu Nakamura , Hiroo Naoi , Kouichi Takenouchi
发明人： Hirofumi Sakita , Syouichi Fujita , Hideji Saiko , Mitsuru Tokuyama , Masatsugu Nakamura , Hiroo Naoi , Kouichi Takenouchi
IPC分类号： G03G1502
CPC分类号： G03G15/0266 , G03G15/0291
摘要： An image-forming apparatus is provided with: a rotatable photoreceptor; a charging device for charging the surface of the photoreceptor to a predetermined electric potential. A device for corona discharging, the charging device has a control electrode for controlling the quantity of corona ions that are allowed to reach the photoreceptor. A latent image forming device for forming an electrostatic latent image on the photoreceptor that has been charged by the charging device by use of light irradiation. There is a developing device for developing the electrostatic latent image by using a developer; and a control voltage supply device for supplying a control voltage to the control electrode and for switching the control voltage to a plurality of stages from a low-voltage side to a high-voltage side until the surface electric potential of the photoreceptor has risen to a predetermined electric potential. This image-forming apparatus prevents carrier rise at the time of a rise of the photoreceptor surface electric potential.
摘要翻译：图像形成装置设置有：可旋转感光体; 用于将感光体的表面充电至预定电位的充电装置。一种用于电晕放电的装置，充电装置具有用于控制允许到达感光体的电晕离子量的控制电极。一种潜像形成装置，用于通过使用光照射在充电装置中对感光体形成静电潜像。存在通过使用显影剂显影静电潜像的显影装置; 以及控制电压供给装置，用于向控制电极提供控制电压，并且将控制电压从低压侧切换到高压侧，直到感光体的表面电位升高到预定电位。该图像形成装置防止感光体表面电位升高时的载体上升。

24. 发明授权

US09006208B2 Agent for treatment of dry eye characterized by combining P2Y2 receptor agonist and hyaluronic acid or salt thereof, method for treating dry eye, and use of the P2Y2 receptor agonist and hyaluronic acid or salt thereof 有权
标题翻译： P2Y2受体激动剂和透明质酸或其盐组合的干眼症治疗剂，治疗干眼症的方法，以及P2Y2受体激动剂和透明质酸或其盐的用途
公开(公告)号：US09006208B2
公开(公告)日：2015-04-14
申请号：US13821717
申请日：2011-09-09
申请人： Yuko Shichijo , Atsuyoshi Dota , Takashi Nagano , Masatsugu Nakamura , Asuka Sakamoto
发明人： Yuko Shichijo , Atsuyoshi Dota , Takashi Nagano , Masatsugu Nakamura , Asuka Sakamoto
IPC分类号： A01N43/04 , A61K31/70 , A61K31/728 , A61K31/675 , A61K45/06 , A61K31/7068 , A61K31/7072 , A61K31/7076
CPC分类号： A61K31/728 , A61K31/675 , A61K31/7068 , A61K31/7072 , A61K31/7076 , A61K45/06 , A61K2300/00
摘要： An agent for treatment of dry eye comprising a combination of a P2Y2 receptor agonist at a therapeutically effective concentration and hyaluronic acid or a salt thereof at a therapeutically effective concentration, which agent has a dosage form of an ophthalmic agent, can promote the secretion of tear remarkably and can improve corneal epithelial disorders remarkably, and is therefore expected to be a novel agent for treatment of dry eye.
摘要翻译：一种用于治疗干眼症的药物，其包括治疗有效浓度的P2Y2受体激动剂和透明质酸或其盐的治疗有效浓度的组合，该药剂具有眼用剂型，可促进泪液的分泌明显地可以改善角膜上皮疾病，因此预期它们是用于治疗干眼症的新型药剂。

25. 发明授权

US08529094B2 Portable electronic device having a plurality of light elements and method of illuminating same 有权
标题翻译：具有多个光元件的便携式电子设备及其照明方法
公开(公告)号：US08529094B2
公开(公告)日：2013-09-10
申请号：US12418508
申请日：2009-04-03
申请人： Masatsugu Nakamura
发明人： Masatsugu Nakamura
IPC分类号： F21V23/04
CPC分类号： G06F1/1684 , G06F1/1616 , G06F1/1656 , G06F1/1677 , H04M1/22 , H04M19/04 , H04M19/048 , H04M2250/12 , H05B33/0842
摘要： A portable electronic device operable to indicate received media is disclosed. A first set of lighting units is used to indicate a received media based on an orientation of the portable electronic device. A second set of the lighting units may be activated based on a change in the orientation of the portable electronic device.
摘要翻译：公开了一种用于指示所接收的媒体的便携式电子设备。第一组照明单元用于基于便携式电子设备的方向来指示所接收的媒体。可以基于便携式电子设备的取向的改变来激活第二组照明单元。

26. 发明申请

US20120232119A1 METHOD FOR TREATING A KERATOCONJUNCTIVAL DISORDER 失效
标题翻译：治疗猝死性疾病的方法
公开(公告)号：US20120232119A1
公开(公告)日：2012-09-13
申请号：US13479485
申请日：2012-05-24
申请人： Atsushi YOSHIDA , Shinichirou Hirai , Masatsugu Nakamura
发明人： Atsushi YOSHIDA , Shinichirou Hirai , Masatsugu Nakamura
IPC分类号： A61K31/41 , A61P27/02
CPC分类号： A61K9/0048 , A61K9/06 , A61K9/08 , A61K9/2018 , A61K31/095 , A61K31/26 , Y10S514/912
摘要： A method for treating a keratoconjunctival disorder, wherein the keratoconjunctival disorder comprises at least one disorder selected from the group consisting of a superficial punctate keratopathy, a corneal epithelial defect, corneal erosion, a corneal ulcer, a conjunctival epithelial defect, keratoconjunctivitis sicca, superior limbic keratoconjunctivitis, filamentary keratoconjunctivitis, keratitis and conjunctivitis, and wherein the method comprises orally administering from 3 mg/kg to 30 mg/kg per day of 2-phenyl-1,2-benzisoselenazol-3(2H)-one or a salt thereof to a patient in need thereof.
摘要翻译：一种治疗角膜结膜疾病的方法，其中所述角膜结膜疾病包括至少一种选自浅表性点状角膜病，角膜上皮缺损，角膜侵蚀，角膜溃疡，结膜上皮缺损，圆锥形结膜炎，上颌骨角结膜炎，角膜结膜炎，角膜炎和结膜炎，并且其中所述方法包括将每日3mg / kg至30mg / kg的2-苯基-1,2-苯并异硒唑（3H）酮或其盐口服给予有需要的患者。

27. 发明申请

US20120225817A1 THERAPEUTIC AGENT FOR GASTROINTESTINAL DISEASE 审中-公开
标题翻译：胃肠病治疗药物
公开(公告)号：US20120225817A1
公开(公告)日：2012-09-06
申请号：US13505627
申请日：2010-11-10
申请人： Teruo Nishida , Makoto Inui , Kenji Matsuura , Masatsugu Nakamura , Takashi Nagano
发明人： Teruo Nishida , Makoto Inui , Kenji Matsuura , Masatsugu Nakamura , Takashi Nagano
IPC分类号： A61K38/07 , A61P29/00 , A61P1/00 , C07K5/103 , A61P1/04
CPC分类号： A61K38/07 , C07K5/1013 , C07K5/1016
摘要： The present invention provides a therapeutic agent and a prophylactic agent for a gastrointestinal disease. A peptide having an amino acid sequence represented by Ser-Ser-Ser-Arg or a pharmaceutically acceptable salt thereof promotes wound healing in a gastrointestinal mucosal tissue, and is therefore useful as a therapeutic agent or a prophylactic agent for a gastrointestinal disease. Further, when (a) a peptide having an amino acid sequence represented by Ser-Ser-Ser-Arg or a pharmaceutically acceptable salt thereof and (b) a peptide having an amino acid sequence represented by Phe-Gly-Leu-Met-NH2 or a pharmaceutically acceptable salt thereof are administered in combination, these medicaments act synergistically and can significantly promote wound healing in a gastrointestinal mucosal tissue.
摘要翻译：本发明提供了治疗剂和胃肠道疾病的预防剂。具有由Ser-Ser-Ser-Arg表示的氨基酸序列的肽或其药学上可接受的盐在胃肠粘膜组织中促进伤口愈合，因此可用作胃肠道疾病的治疗剂或预防剂。此外，（a）具有Ser-Ser-Ser-Arg表示的氨基酸序列的肽或其药学上可接受的盐和（b）具有由Phe-Gly-Leu-Met-NH 2表示的氨基酸序列的肽或其药学上可接受的盐组合施用，这些药物协同作用并且可显着促进胃肠粘膜组织中的伤口愈合。

28. 发明授权

US08222283B2 Method for treating a keratoconjunctival disorder 失效
标题翻译：治疗角膜结膜疾病的方法
公开(公告)号：US08222283B2
公开(公告)日：2012-07-17
申请号：US11920477
申请日：2006-05-17
申请人： Atsushi Yoshida , Shinichirou Hirai , Masatsugu Nakamura
发明人： Atsushi Yoshida , Shinichirou Hirai , Masatsugu Nakamura
IPC分类号： A61K31/42
CPC分类号： A61K9/0048 , A61K9/06 , A61K9/08 , A61K9/2018 , A61K31/095 , A61K31/26 , Y10S514/912
摘要： An object of the present invention is to provide a new medicinal use of 2-phenyl-1,2-benzisoselenazol-3(2H)-one or a salt thereof. 2-Phenyl-1,2-benzisoselenazol-3(2H)-one or a salt thereof exhibits an excellent prevention and improvement effect in corneal disorder models, and is therefore useful as a preventive or therapeutic agent for a keratoconjunctival disorder such as dry eye, superficial punctate keratopathy, corneal epithelial defects, corneal erosion, corneal ulcer, conjunctival epithelial defects, keratoconjunctivitis sicca, superior limbic keratoconjunctivitis, filamentary keratoconjunctivitis, keratitis or conjunctivitis.
摘要翻译：本发明的目的是提供2-苯基-1,2-苯并异硒唑（3H）酮或其盐的新药用途。 2-苯基-1,2-苯并异硒唑-3（2H） - 酮或其盐在角膜障碍模型中表现出优异的预防和改善作用，因此可用作角膜结膜疾病如干眼症的预防或治疗剂，浅表性点状角膜病变，角膜上皮缺损，角膜侵蚀，角膜溃疡，结膜上皮缺损，结膜炎角膜结膜炎，上限角膜结膜炎，丝状角膜结膜炎，角膜炎或结膜炎。

29. 发明授权

US07358255B2 Therapeutic agent for keratoconjunctival disorder 失效
标题翻译：角膜结膜疾病治疗剂
公开(公告)号：US07358255B2
公开(公告)日：2008-04-15
申请号：US10576719
申请日：2004-10-22
申请人： Masatsugu Nakamura , Shin-ichiro Hirai
发明人： Masatsugu Nakamura , Shin-ichiro Hirai
IPC分类号： A61K31/427
CPC分类号： A61K31/427 , C07D417/12
摘要： Object of the present invention is to search a novel pharmaceutical use of 5-[4-(6-methoxy-1-methyl-1H-benzimidazol-2-ylmethoxy)benzyl]thiazolidine-2,4-dione being a condensed heterocyclic compound, or a salt thereof. 5-[4-(6-methoxy-1-methyl-1H-benzimidazol-2-ylmethoxy)benzyl]thiazolidine-2,4-dione or a salt thereof can exert an excellent effect to promote healing in a dry eye model, and is useful as a therapeutic agent for keratoconjunctival disorders such as dry eyes, corneal ulcer, keratitis, conjunctivitis, superficial punctate keratopathy, corneal epithelial defects, conjunctival epithelial defects, keratoconjunctivitis sicca, superior limbic keratoconjunctivitis and filamentary keratitis.
摘要翻译：本发明的目的是搜索作为稠合杂环化合物的5- [4-（6-甲氧基-1-甲基-1H-苯并咪唑-2-基甲氧基）苄基]噻唑烷-2,4-二酮的新药用途，或其盐。 5- [4-（6-甲氧基-1-甲基-1H-苯并咪唑-2-基甲氧基）苄基]噻唑烷-2,4-二酮或其盐可以在干眼模型中发挥促进愈合的优异效果，可用作干眼症，角膜溃疡，角膜炎，结膜炎，浅表性点状角膜病，角膜上皮缺损，结膜上皮缺损，角膜结膜炎，角膜结膜炎，丝状角膜炎等角膜结膜疾病的治疗剂。

30. 发明申请

US20070093514A1 Therapeutic agent for keratoconjunctival disorder 失效
标题翻译：角膜结膜疾病治疗剂
公开(公告)号：US20070093514A1
公开(公告)日：2007-04-26
申请号：US10576402
申请日：2004-10-29
申请人： Masatsugu Nakamura , Shin-ichiro Hirai
发明人： Masatsugu Nakamura , Shin-ichiro Hirai
IPC分类号： A61K31/517 , A61K31/421
CPC分类号： A61K31/517 , A61K9/0048 , A61K31/421
摘要： An object of the present invention is to discover a new medicinal use of 5-[4-[[3-methyl-4-oxo-3,4-dihydro-2-quinazolinyl]methoxy]p henylmethyl]thiazolidine-2,4-dione and N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine. Both of the compounds exert an excellent improving effect on corneal disorder models and is useful as a therapeutic agent for a keratoconjunctival disorder such as dry eyes, corneal ulcer, keratitis, conjunctivitis, superficial punctate keratopathy, corneal epithelial defects, conjunctive epithelial defects, keratoconjunctivitis sicca, superior limbic keratoconjunctivitis and filamentary keratitis.
摘要翻译：本发明的目的是发现5- [4 - [[3-甲基-4-氧代-3,4-二氢-2-喹唑啉基]甲氧基]苯甲基甲基]噻唑烷-2,4-二酮的新药物用途，二酮和N - [（4-甲氧基苯氧基）羰基] -N - [[4- [2-（5-甲基-2-苯基-4-恶唑基）乙氧基]苯基]甲基]甘氨酸。这两种化合物对角膜障碍模型具有极好的改善作用，可用作干眼症，角膜溃疡，角膜炎，结膜炎，浅表性点状角膜病，角膜上皮缺损，结膜上皮缺损，结膜炎角膜结膜炎等角膜结膜疾病的治疗剂，上限角膜结膜炎和丝状角膜炎。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式